Pfizer Reduces Stake in BioNTech; Candel Pauses Pancreatic Cancer Program
Pfizer reduced its stake in BioNTech by 54.7%, retaining approximately 1.66 million shares valued at $163.5 million as of September 30, 2025.
The divestment is part of Pfizer's strategic rebalancing to address patent cliffs and fund acquisitions, including the $10 billion buyout of Metsera.
Despite the stake reduction, both Pfizer and BioNTech confirm that their collaboration remains unchanged.
Candel Therapeutics has paused its pancreatic cancer program, reflecting broader industry trends of pipeline reassessment and cost management.
Pfizer's move aligns with a shift from pandemic-era revenues to high-growth therapeutic areas such as obesity and cardiometabolic diseases.
BioNTech continues to focus on oncology, with notable partnerships and assets in cancer therapy development.